(MENAFNEditorial)
FOR IMMEDIATE RELEASE Illinois – United States – April 242015 (PR Buzz):The global treatment market for Duchenne Muscular Dystrophy (DMD) will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5% from approximately $8.2 million in 2014 to $990 million by 2019.
Reportstack’s latest report "OpportunityAnalyzer: Duchenne Muscular Dystrophy-Opportunity and Market Analysis to 2019" states that this growth will occur across six major markets: the US France Germany Italy Spain and the UK. Combined the five European countries will contribute 55.2% to the total market value by 2019 while the US will account for 44.8%.
According to Nikhilesh Sanyal Ph.D. GlobalData's Analyst covering Immunology the primary driver behind this impressive expansion will be the market entry of PTC Therapeutics’ Translarna Sarepta Therapeutics’ eteplirsen and BioMarin/Prosensa’s drisapersen.
“These mutation-specific drugs are expected to have a high price point due to their novelty efficacy and orphan drug status and will contribute 85.6% to the DMD treatment arena by 2019. While Translarna is expected to be the top-selling DMD drug by 2019 exon-51-skipping therapies drisapersen and eteplirsen will also be a hotspot for growth thanks to their rapid clinical development and significant demand.
“Despite rapid developments in DMD therapeutics over the last five years there remains a large unmet need among patients who are not amenable to these mutation-specific drugs and who would benefit from effective disease-modifying therapies.”
However the analyst adds that drug developers will need to overcome a number of challenges to take advantage of this major opportunity.
“There is currently a lack of standardization for measuring clinical efficacy across all stages of DMD. While most studies use the change in the six-minute walk test as the primary clinical endpoint this applies only to ambulant patients and therefore excludes non-ambulant individuals as well as children under the age of five.
“Furthermore the high cost of novel disease-modifying drugs means that their reimbursement by local health authorities and insurance companies may be prevented following their entry into the arena” the analyst concludes.
About Reportstack:
Reportstack is one of the leading distributors of market research reports in the world today. We host more than 200000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack members with cutting edge research products to facilitate strategic business decisions.
Contact:
Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
###
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.